HC Wainwright Has Negative Outlook for AUTL Q2 Earnings

Key Points

• HC Wainwright cut its Q2 2026 EPS estimate for Autolus to ($0.34) from ($0.31) but retained a Buy rating and a $9.00 price target.
• Autolus reported Q1 EPS of ($0.34) on March 27, missing the consensus ($0.27) and showing a very negative net margin (381.4%) and return on equity (-99.05%).
• The stock trades near $1.47 with a market cap of about $391M; analysts' consensus is a "Moderate Buy" with an average target of roughly $8.50, despite recent price volatility and ~73% institutional ownership.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.34) for the quarter, down from their previous forecast of ($0.31). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Autolus Therapeutics' Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.74) EPS, FY2029 earnings at ($0.38) EPS and FY2030 earnings at ($0.22) EPS.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.07). Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%. The company had revenue of $24.29 million during the quarter, compared to analysts' expectations of $23.92 million.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday. Jefferies Financial Group raised shares of Autolus Therapeutics to a "strong-buy" rating in a research report on Monday, April 20th. Truist Financial raised shares of Autolus Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. Zacks Research raised shares of Autolus Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, March 13th. Finally, Needham & Company LLC reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $8.50.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.47 on Monday. Autolus Therapeutics has a 1-year low of $1.15 and a 1-year high of $2.70. The stock has a market cap of $391.23 million, a PE ratio of -1.36 and a beta of 1.93. The firm has a fifty day moving average price of $1.50 and a 200 day moving average price of $1.51.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. Independent Advisor Alliance purchased a new position in Autolus Therapeutics during the 4th quarter worth $28,000. Marex Group plc purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at about $28,000. SmartHarvest Portfolios LLC acquired a new position in shares of Autolus Therapeutics during the fourth quarter worth about $43,000. Caitong International Asset Management Co. Ltd purchased a new position in Autolus Therapeutics during the third quarter worth about $46,000. Finally, R Squared Ltd raised its holdings in Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company's stock worth $50,000 after purchasing an additional 8,730 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.